Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy
ConclusionsIn this study, patients treated with cetuximab and radiotherapy, showing high baseline of both ADCC and EGFR3+, have significant higher probability of achieving a complete response and a long overall survival compared to the others.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Carcinoma | Erbitux | Head and Neck Cancer | Immunotherapy | Skin Cancer | Squamous Cell Carcinoma | Study